Research question
How does retatrutide compare with other research peptides?
In the research literature, retatrutide is described as a peptide that engages three receptors: GLP-1, GIP and glucagon. Other lyophilised research peptides sold for incretin work are described differently. One class is discussed as acting at the GLP-1 receptor alone. Another is discussed as a dual agonist at GIP and GLP-1 receptors. Those are statements about receptor pharmacology in papers. They are not a ranking of products and not a reason to use any of them outside a protocol.
GetReta does not stock those other peptides. The catalogue is one compound in two labelled masses, 30 mg at £60 and 40 mg at £70. Comparing a certificate still means the same thing: lot, identity, HPLC purity, mass-spec result, test date. A higher labelled milligram is not a different receptor profile. The 40 mg vial is more of the same retatrutide.
No brand name of a licensed product belongs on this comparison. Those names refer to medicines with authorisations. GetReta vials do not. Research use only. Not for human or veterinary use.